Ingo G.H. Schmidt‐Wolf

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations

Medicine, Oncology, Chemotherapy +10

<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk et al. · Journal of Clinical Oncology · 2011 · 450 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Hendrik Pels, Ingo G.H. Schmidt‐Wolf, Axel Glasmacher et al. · Journal of Clinical Oncology · 2003 · 423 citations

Medicine, Oncology, Pharmacotherapy +13

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman et al. · Journal of Clinical Oncology · 2010 · 334 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

Ingo G.H. Schmidt‐Wolf, Petja Lefterova, Bela Mehta et al. · PubMed · 1993 · 328 citations

Life Sciences, Immunology, Oncology +17